Avenue Therapeutics, Inc. (ATXI) Ownership
ATXI ownership summary
as of October 21, 2026- Institutions
- 4.0% of shares outstanding
- Insiders
- 13.51% of shares outstanding
- Shares outstanding
- 3.3M
- Float
- 2.9M shares available to trade
- Short interest
- 2.44% 92K shares short
- Days to cover
- 0.72 short interest down 40.5% vs prior month
- Institutions 3.97%
- Insiders 13.51%
- Other investors 82.52%
ATXI top institutional holders
12 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 6.82% | 140K | $56,588 | +140,000 (0.0%) | December 31, 2024 |
| 2 | BOOTHBAY FUND MANAGEMENT, LLC | 2.00% | 41K | $16,608 | +41,089 (0.0%) | December 31, 2024 |
| 3 | UBS Group AG | 0.39% | 7,920 | $3,201 | +1,777 (+28.9%) | December 31, 2024 |
| 4 | Tower Research Capital LLC | 0.15% | 3,096 | $1,251 | +1,356 (+77.9%) | December 31, 2024 |
| 5 | Wells Fargo & Co | 0.02% | 500 | $202 | −61 (−10.9%) | December 31, 2024 |
| 6 | Bank of America Corp | <0.01% | 14 | $6 | +4 (+40.0%) | December 31, 2024 |
| 7 | SBI Securities Co Ltd | <0.01% | 9 | $4 | +9 (0.0%) | December 31, 2024 |
| 8 | Moss Adams Wealth Advisors LLC | 0.00% | — | — | −11,000 (−100.0%) | December 31, 2024 |
| 9 | Sabby Management LLC | 0.00% | — | — | −63,060 (−100.0%) | December 31, 2024 |
| 10 | JPMorgan Chase & Co | 0.00% | — | — | −2 (−100.0%) | December 31, 2024 |
| 11 | Northern Trust Investments N A | 0.00% | — | — | −68 (−100.0%) | December 31, 2024 |
| 12 | Armistice Capital, LLC | 0.00% | — | — | −115,000 (−100.0%) | December 31, 2024 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 12, 6 holders added 184K shares and 6 cut 189K.
ATXI top mutual fund and ETF holders
13 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.32% | 6,522 | $2,636 | −71 (−1.1%) | January 31, 2025 |
| 2 | Fidelity Series Total Market Index | 0.08% | 1,584 | $640 | — | January 31, 2025 |
| 3 | Vanguard Institutional Extnd Mkt Idx Tr | 0.03% | 618 | $250 | — | January 31, 2025 |
| 4 | Spartan Extended Market Index Pool E | <0.01% | 71 | $29 | +71 (0.0%) | January 31, 2025 |
| 5 | NT Ext Equity Mkt Idx Fd - NL | <0.01% | 7 | $3 | — | December 31, 2024 |
| 6 | Northern Trust Extended Eq Market Idx | <0.01% | 6 | $2 | — | December 31, 2024 |
| 7 | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | <0.01% | 6 | $2 | — | December 31, 2024 |
| 8 | NT Ext Equity Mkt Idx Fd - L | <0.01% | 6 | $2 | — | December 31, 2024 |
| 9 | State St US Extended Mkt Indx NL Cl C | <0.01% | 3 | $1 | — | February 28, 2025 |
| 10 | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 0.00% | 1 | $0 | — | September 30, 2024 |
| 11 | SSgA U.S. Total Market Index Strategy | 0.00% | 1 | $0 | — | June 30, 2024 |
| 12 | NT Ext Eq Mkt Indx Fd DC Lend T4 | 0.00% | 1 | $0 | +1 (0.0%) | December 31, 2024 |
| 13 | NT Ext Eq Mkt Indx Fd DC Lend T3 | 0.00% | 1 | $0 | +1 (0.0%) | December 31, 2024 |
Funds report holdings monthly or quarterly; dates differ by fund.
ATXI insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-05 | Jay D Kranzler | Sell | $2.24 | 61 | $137 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ATXI shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ATXI
Institutional investors own 4.0% of Avenue Therapeutics's shares and insiders 13.51%. The largest holder is Ikarian Capital, LLC with 6.82% of the shares (140K), as of December 31, 2024. Among the top 12 institutions, 6 added shares and 6 reduced their stake in the latest filings. Short interest is 2.44% of the float, or 0.72 days of average trading volume. The share count rose 446.6% since 2015.
Related: ATXI analyst forecast, ATXI key metrics. See the ATXI stock overview for the latest quote and news.
ATXI ownership FAQ
Who owns the most Avenue Therapeutics stock?
The largest shareholders of Avenue Therapeutics are Ikarian Capital, LLC (6.82%), BOOTHBAY FUND MANAGEMENT, LLC (2.00%), UBS Group AG (0.39%), Tower Research Capital LLC (0.15%), Wells Fargo & Co (0.02%).
What percentage of Avenue Therapeutics is owned by institutions?
Institutions hold 4.0% of Avenue Therapeutics's shares outstanding; insiders hold 13.51%.
Which funds own Avenue Therapeutics?
The largest fund holders of Avenue Therapeutics are Fidelity Extended Market Index (0.32%), Fidelity Series Total Market Index (0.08%), Vanguard Institutional Extnd Mkt Idx Tr (0.03%), Spartan Extended Market Index Pool E (<0.01%), NT Ext Equity Mkt Idx Fd - NL (<0.01%).
What is Avenue Therapeutics's short interest?
92K shares of Avenue Therapeutics were sold short, 2.44% of the float; at the average daily volume it would take 0.72 days to cover.
Are insiders buying or selling Avenue Therapeutics?
Of the latest 1 reported insider transactions in Avenue Therapeutics (since November 5, 2024), 0 were purchases and 1 were sales.
How many shares of Avenue Therapeutics are outstanding?
Avenue Therapeutics has 3.3M shares outstanding, of which 2.9M are in the public float.